SREBF1 and metabolic dysfunction-associated steatotic liver disease: Moreover, VitD treatment significantly (p < 0.05) abolished the HFFD-mediated downregulation of SREBP-1-c and significantly promoted the mRNA expression of PPAR-α and IRS-2 in the liver of the NAFLD + VitD group versus the NAFLD group.